Skip to the main content.
ADRIATIC

Lung Cancer

ADRIATIC

Manufactured by: AstraZeneca
Product name: Imfinzi® (Durvalumab)

About the ADRIATIC Trial

The ADRIATIC trial is a Phase III, randomized, double-blind study evaluating the role of durvalumab ± tremelimumab as consolidation therapy in patients with limited-stage small cell lung cancer (LS-SCLC) who have completed concurrent chemoradiotherapy (cCRT). Patients were randomized to receive durvalumab, durvalumab plus tremelimumab, or placebo following cCRT. The co-primary endpoints were overall survival (OS) and progression-free survival (PFS). Durvalumab monotherapy demonstrated a statistically significant improvement in both OS (hazard ratio [HR] 0.73; p=0.0104) and PFS (HR 0.76; p=0.0161) compared to placebo. These benefits were consistent across predefined clinical subgroups. The findings were presented at the 2024 ASCO Annual Meeting by Dr. David R. Spigel.

 

Table of Contents

Major Presentations and Milestones

ADRIATIC Trial design, results, and conclusions

ADRIATIC Sentiments and Criticisms

 ADRIATIC Temporal Sentiment Arc

Professional Resources : Interactive Tweet History, Influence Diagram, Sentiment Table, AI Chatbot

ADRIATIC Trial: Major Presentations and Milestones

Primary speakers driving the story: via Dr. Ryaz Shah from ASCO24, "ADRIATIC. A brilliant presentations by @DavidRSpigel and discussion by @LaurenByersMD..."

Jarushka Naidoo, MD (ASCO 2024 plenary live coverage): “#ASCO24 Plenary🔥 Ph III ADRIATIC trial of consolidation Durva +/-Treme post cCRT for LS SCLC: - benefit in mOS 55.9 v 33.4m (HR 0.73, p=0.01) & mPFS 16.6 v 9.2m … First advance in 30+yrs in LS SCLC” https://twitter.com/DrJNaidoo/status/1797369436430594290

A/Prof Shankar Siva, MD, PhD (ASCO 2024 plenary; radiation oncology perspective): “pivotal ADRIATIC ph III … durvalumab after chemoradiotherapy (cCRT) ± PCI … ⬆️ OS (HR 0.73), median OS 55.9 vs 33.4. Grade 3/4 AEs 24.3% vs 24.2%. Practice changing!!!” https://twitter.com/_ShankarSiva/status/1797367226405724564

Stephen V. Liu, MD (thoracic oncology; discussant takeaways): “Dr. @LaurenByersMD with a wonderful discussion of ADRIATIC at #ASCO24 – highlighting a much greater impact on OS with immunotherapy in the limited stage setting than seen in extensive stage.” https://twitter.com/StephenVLiu/status/1797369428226494869

KOL reactions to the OS presentation and its significance

Noemi Reguart, MD: “Second practice changing trial of the day… OS/PFS meet (3-y FUP): mOS 55.9 vs 33.4 (HR 0.73) and 24% reduction in risk of PFS/death (16.6 vs 9.2 mo; HR 0.76)” https://twitter.com/NReguart/status/1797369372844994874

Nathan A. Pennell, MD, PhD, FASCO: “Standing ovations as KM curves revealed… practice changing!” https://twitter.com/n8pennell/status/1797369975868367054

Salma Jabbour, MD: “ADRIATIC study is the new standard of care for limited stage small cell lung cancer… improved mOS to 56 mo from 33 mo (placebo) and mPFS of 17 months vs 9 mo” https://twitter.com/SalmaJabbour1/status/1797369378771448318

Erika Hamilton, MD: “So proud of @DavidRSpigel for an excellent presentation… transforming results… Big win for patients!” https://twitter.com/ErikaHamilton9/status/1797368720076980476

Abdulaziz AlJassim, MD (DrZ_84): “One more Standing Ovation… Durvalumab… A new standard of care” https://twitter.com/DrZ_84/status/1797368826935259189

 

ADRIATIC Trial design, results, and conclusions

Core design/results (as amplified by KOLs)

Overview amplified by KOLs

  • Setting: Limited-stage SCLC after concurrent chemoradiotherapy (cCRT), consolidation durvalumab vs placebo; ± PCI allowed.
  • Dual primary endpoints: Overall survival (OS) and progression-free survival (PFS).
  • Efficacy: mOS 55.9 vs 33.4 months (HR 0.73); mPFS 16.6 vs 9.2 months (HR 0.76).
  • Safety: Grade 3/4 AEs balanced (~24% both arms); pneumonitis noted by several KOLs.

KOL deep-dives on design/results

Treatment landscape context


 

ADRIATIC Trial Sentiments from KOLs: standard of care and critical appraisals

Strongly supportive/SoC-leaning voices

Shankar Siva, MD, PhD (practice-changing declaration): https://twitter.com/_ShankarSiva/status/1797367226405724564

Salma Jabbour, MD (“new standard of care” with OS/PFS specifics): https://twitter.com/SalmaJabbour1/status/1797369378771448318

Abdulaziz AlJAssim, MD (DrZ_84) (“A new standard of care”): https://twitter.com/DrZ_84/status/1797368826935259189

SuyogCancer, MD (“This should be standard of care”): https://twitter.com/SuyogCancer/status/1797367479930609744

Erika Hamilton, MD (“transforming results… Big win for patients”): https://twitter.com/ErikaHamilton9/status/1797368720076980476

Other KOL perspectives 

Henning Willers, MD (RT strategy/toxicity): “Stunning results‼️ … Make chest RT less toxic or keep trying to dose escalate? … G3+ esophagitis rates remain too high nationally! More or less PCI?” https://twitter.com/HenningWillers/status/1797390500837638186

Corinne Faivre-Finn, MD, PhD (PCI vs MRI surveillance; optimization): “Next key question 👉 PCI+MR surveillance vs MR surveillance … recruit to PRIMALUNG … MAVERICK…” https://twitter.com/finn_corinne/status/1797438492437602317


ADRIATIC Temporal Sentiment Arc

2024 (ASCO 2024 plenary; rapid shift to “practice-changing”) Primary/KOL tweets: https://twitter.com/DrJNaidoo/status/1797369436430594290

https://twitter.com/_ShankarSiva/status/1797367226405724564

https://twitter.com/ASCO/status/1797370147587379373

https://twitter.com/NReguart/status/1797369372844994874

https://twitter.com/n8pennell/status/1797369975868367054

Tone: Immediate enthusiasm with repeated “practice-changing/new SOC” language. KOLs underscore the magnitude of benefit (mOS 55.9 vs 33.4 months, HR 0.73; mPFS 16.6 vs 9.2 months, HR 0.76) and balanced Grade 3/4 AEs. Momentum coalesces quickly toward adoption after cCRT in LS-SCLC.

2024 (ESMO2024)

Tone: Deeper dives and curated explainers spread the findings to broader clinical audiences. Cross specialty discussion of subset analysis from ESMO24 and practical application of the ADRIATIC Trial findings.

2025 Discussions: International voices echo sustained adoption and explore center‑specific pathways (RT techniques, PCI vs MRI surveillance, toxicity monitoring). Discussions emphasize patient selection, multidisciplinary coordination, CNS effects, with a key focus on Dr. Suresh Senan's presentation at #ELCC25

Tone: The arc progresses from pre‑plenary anticipation to a decisive “practice‑changing” consensus at ASCO 2024, followed by an implementation‑focused phase that refines PCI/RT strategies and toxicity surveillance. Through late 2024 and into 2025, international and cross‑disciplinary threads reinforce adoption while iterating on practical optimization and patient selection.

sentiment trend anchor